trial · primary record
Zedoresertib
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 116 |
| Primary completion | 2028-09 |
| Primary endpoint | Phase 1 (Dose Escalation): Number of Participants Experiencing Dose-limiting Toxicities (DLTs) |
| Registry ID | NCT05765812 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:09.095Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05765812
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.